IPA Insider Trading
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$34,263.30
Insider Selling (Last 12 Months): C$0.00
ImmunoPrecise Antibodies Share Price & Price History
Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 10/25/2021 12:05 PM ET
ImmunoPrecise Antibodies Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
12/16/2024 | Jennifer Lynne Bath | Senior Officer | Buy | 12,300 | C$0.61 | C$7,475.33 | | |
3/27/2024 | Jennifer Lynne Bath | Senior Officer | Buy | 4,211 | C$1.56 | C$6,567.90 | | |
3/25/2024 | Jennifer Lynne Bath | Senior Officer | Buy | 1,000 | C$1.54 | C$1,538.50 | | |
3/21/2024 | Jennifer Lynne Bath | Senior Officer | Buy | 3,000 | C$1.38 | C$4,140.00 | | |
3/21/2024 | Mitchell Levine | Director | Buy | 10,000 | C$1.43 | C$14,256.00 | | |
3/18/2024 | Ilse Roodink | Senior Officer | Buy | 200 | C$1.43 | C$285.58 | | |
12/20/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 2,000 | C$1.35 | C$2,698.40 | | |
12/18/2023 | Mitchell Levine | Director | Buy | 10,000 | C$1.38 | C$13,834.00 | | |
12/8/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 20,000 | C$1.00 | C$20,000.00 | | |
11/9/2023 | Dirk Witters | Director | Buy | 1,000 | C$1.70 | C$1,700.00 | | |
11/1/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 1,000 | C$2.07 | C$2,066.60 | | |
10/27/2023 | Dirk Witters | Director | Buy | 950 | C$1.82 | C$1,729.00 | 950 | |
10/26/2023 | Kristin Taylor | Senior Officer | Buy | 5,000 | C$1.35 | C$6,750.00 | | |
10/25/2023 | Barry Alan Springer | Director | Buy | 10,000 | C$1.41 | C$14,090.00 | | |
10/23/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 900 | C$1.24 | C$1,115.91 | | |
9/22/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 1,000 | C$1.98 | C$1,980.40 | | |
9/18/2023 | Jennifer Lynne Bath | Senior Officer | Buy | 1,000 | C$1.89 | C$1,890.00 | | |
3/21/2023 | Frederic Chabot | Director | Buy | 605 | C$2.99 | C$1,808.95 | | |
9/23/2022 | Gregory Stuart Smith | Director | Buy | 3,500 | C$5.41 | C$18,935.00 | 42,500 | |
9/22/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 500 | C$6.01 | C$3,005.64 | 98,798 | |
9/20/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 100 | C$6.49 | C$648.93 | 98,098 | |
9/15/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 44 | C$6.45 | C$283.79 | 94,942 | |
8/17/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 200 | C$7.42 | C$1,483.47 | 94,398 | |
8/15/2022 | Gregory Stuart Smith | Director | Buy | 5,000 | C$6.93 | C$34,670.00 | 39,000 | |
8/15/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 100 | C$7.04 | C$703.77 | 93,398 | |
8/12/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 400 | C$7.13 | C$2,850.90 | 91,098 | |
8/9/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 5 | C$5.41 | C$27.03 | 87,703 | |
8/4/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 200 | C$5.22 | C$1,044.48 | 87,348 | |
8/1/2022 | Ilse Roodink | Senior Officer | Buy | 100 | C$5.56 | C$555.52 | 1,042 | |
5/11/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 50 | C$5.76 | C$287.95 | 43,682 | |
5/9/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 299 | C$6.24 | C$1,865.76 | 42,631 | |
5/4/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 90 | C$7.28 | C$655.13 | 42,049 | |
4/27/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 250 | C$7.09 | C$1,771.65 | 41,584 | |
4/22/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 100 | C$7.21 | C$720.72 | 40,604 | |
4/11/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 600 | C$7.27 | C$4,362.12 | 38,904 | |
4/6/2022 | Carla Cherry Dahl | Senior Officer | Buy | 10,000 | C$7.49 | C$74,875.00 | 10,000 | |
4/1/2022 | Jennifer Lynne Bath | Senior Officer | Buy | 100 | C$6.31 | C$631.25 | 36,584 | |
SEC Filings (Institutional Ownership Changes) for ImmunoPrecise Antibodies (TSE:IPA)
IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.
Read More on ImmunoPrecise Antibodies
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of ImmunoPrecise Antibodies?